Irina Gitlin
YOU?
Author Swipe
View article: A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases
A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases Open
Background Mucin disulfide cross-links mediate pathologic mucus formation in muco-obstructive lung diseases. MUC-031, a novel thiol-modified carbohydrate compound, cleaves disulfides to cause mucolysis. The aim of this study was to determi…
View article: Method and apparatus for fluid dispersion
Method and apparatus for fluid dispersion Open
A microfluidic method and device for focusing and/or forming discontinuous sections of similar or dissimilar size in a fluid is provided. The device can be fabricated simply from readily-available, inexpensive material using simple techniq…
View article: Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19
Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19 Open
The redox status of the cysteine-rich SARS-CoV-2 spike glycoprotein (SARS-2-S) is important for the binding of SARS-2-S to angiotensin-converting enzyme 2 (ACE2), suggesting that drugs with a functional thiol group (“thiol drugs”) may clea…
View article: Thiol drugs decrease SARS-CoV-2 lung injury<i>in vivo</i>and disrupt SARS-CoV-2 spike complex binding to ACE2<i>in vitro</i>
Thiol drugs decrease SARS-CoV-2 lung injury<i>in vivo</i>and disrupt SARS-CoV-2 spike complex binding to ACE2<i>in vitro</i> Open
Neutrophil-induced oxidative stress is a mechanism of lung injury in COVID-19, and drugs with a functional thiol group (“thiol drugs”), especially cysteamine, have anti-oxidant and anti-inflammatory properties that could limit this injury.…